首页> 外文期刊>Forbes >Miracle In the Midwest
【24h】

Miracle In the Midwest

机译:中西部的奇迹

获取原文
获取原文并翻译 | 示例
           

摘要

David C. Schwartz is right at home in the dark. That's where his fluorescent microscopes can do their work, scanning thousands of samples of DNA that make a slow crawl across computer screens and methodically map the human genome. All this activity is packed into a cramped room inside a lab at the University of Wisconsin at Madison. "Most people think I came here because I hated New York," he says with a boyish smile and a twitch of the mustache that curls over his lip. "I came here to start a company." Five years ago Schwartz, now 49, left Greenwich Village and a professorship at New York University and moved to Madison, taking 15 of his students and staff with him. He founded Opgen j in 2001 and raised $3 million in venture and seed capital. Years away from producing revenue or profits, Opgen has a lofty goal: Extract a patient's DNA from a cell, place it on a glass chip and rapidly scan it, marking variations with bar codes similar to SKUs in the supermarket. Compare the sample with codes for healthy and cancerous cells so you can catch a burgeoning disease early on and treat it. Such a diagnostic would be quick―walk in for a physical, give blood and emerge with a genome scan. At an anticipated $5,000, it would cost considerably more than anything on the market today; but current DNA tests, working with pieces of the genome, aren't as accurate. "He is brilliant, the classic mad scientist," says John T. Byrnes, executive managing director of Mason Wells, a Milwaukee private equity firm that has invested $20 million in Wisconsin startups, including Opgen.
机译:David C. Schwartz在黑暗中正好在家。那是他的荧光显微镜可以完成工作的地方,可以扫描数千个DNA样本,这些样本可以在计算机屏幕上缓慢爬行,并有条不紊地绘制人类基因组图。所有这些活动都包装在麦迪逊威斯康星大学实验室的一个狭窄房间中。 “大多数人认为我来这里是因为我讨厌纽约,”他带着男孩般的微笑和and缩在嘴唇上的胡须抽搐着说道。 “我来这里是为了创办公司。”五年前,现年49岁的施瓦兹(Schwartz)离开格林威治村(Greenwich Village)并在纽约大学(New York University)担任教授,并搬到麦迪逊(Madison),带走了15名学生和教职员工。他于2001年创立了Opgen j,并筹集了300万美元的风险投资和种子资金。距产生收入或利润已有数年的时间,Opten的远大目标是:从细胞中提取患者的DNA,将其放在玻璃芯片上并快速扫描,并用类似于超市中SKU的条形码标记变化。将样本与健康和癌细胞的代码进行比较,这样您就可以及早发现新兴疾病并进行治疗。这样的诊断将是快速的–身体检查,输血并通过基因组扫描出现。预计价格为5,000美元,它的成本将比当今市场上的任何产品高得多。但是目前的DNA测试,与基因组片段一起工作,还不够准确。密尔沃基私人股权投资公司梅森·威尔斯(Mason Wells)的执行董事约翰·T·伯恩斯(John T. Byrnes)说:“他是一位杰出的科学家,是一位疯狂的经典科学家。”梅森威尔斯向包括Opgen在内的威斯康星州初创企业投资了2000万美元。

著录项

  • 来源
    《Forbes》 |2004年第11期|p.120-122126128|共5页
  • 作者

    MARK TATGE;

  • 作者单位
  • 收录信息 美国《科学引文索引》(SCI);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 世界经济问题;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号